Virtuoso Therapeutics to Present Preclinical Findings on Two Best-in-Class Bispecific Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting

On March 23, 2022 Virtuoso Therapeutics, Inc., a private oncology-focused company developing novel bispecific antibody and antibody drug conjugate (ADC) therapies, reported that it will present two posters highlighting the preclinical data from leading bispecific antibody programs at the American Associate for Cancer Research (AACR) (Free AACR Whitepaper) 2022 Annual Meeting (Press release, Virtuoso Therapeutics, MAR 23, 2022, View Source [SID1234610768]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details of the Company’s presentations at the AACR (Free AACR Whitepaper) are as follows:

Poster Presentation #5385:

Title: Multiple modes of action of the CD38 x ICAM-1 bispecific antibody
Session Category: Experimental and Molecular Therapeutics
Session Title: Mechanisms of Drug Action
Presenting Author: Xiaocheng Chen, Ph.D. VP of Antibody Therapeutics
Date/Time: Friday, April 8, 2022, 12:00 – 1:00 p.m. Central
Location: E-Poster Website

Poster Presentation #3430:

Title: CD47 x ICAM-1 bispecific antibody represents a novel approach for treating ICAM-1 overexpressing tumors
Session Category: Clinical Research Excluding Trials
Session Title: Combination Immunotherapies / Therapeutic Antibodies
Presenting Author: Xinhua Wang, Ph.D. Director of Antibody Engineering
Date/Time: Tuesday, April 12, 2022, 1:30 – 5:00 p.m. Central
Location: E-Poster Website

Virtuoso bispecific antibodies confer greater tumor selectivity than monoclonal antibodies. This greater selectivity allows enhanced efficacy with strong effector functions, and improved safety profile. Posters will be available at www.virtuosotherapuetics.com after the meeting.